1. Do you currently offer a clinical testing service for BRAF mutation in solid tissue, specifically melanoma? (Yes, No, currently in development)

2. Which methodology(ies) do you use for BRAF testing in melanoma? e.g. Real time PCR (QPCR), High resolution melting curve analysis (HRMCA), Sanger sequencing, Next Generation Sequencing (NGS), Pyrosequencing, Immunohistochemistry (IHC), Fluorescence In Situ Hybridisation (FISH), Other (please specify). If you use a specific kit I would be grateful if you could provide the name of the kit you use.

3. Which BRAF mutations does your methodology(ies) cover? E.g. V600E, V600K, V600D, V600R etc.

4. What is your current laboratory turnaround time for BRAF testing in melanoma?

5. What is the level of sensitivity of your BRAF methodology(ies)?

6. I understand that molecular testing in FFPE tissue can be difficult due to tissue quality and/or quantity. What would you estimate is your current failure rate for BRAF testing for melanoma?

7. Approximately how many BRAF tests for melanoma would you conduct per month or year (whichever time period is most convenient for you to estimate)?

8. Of the BRAF tests performed for melanoma, please estimate how many (or what percentage) are found to be positive for a mutation?

9. Of the positive tests, please estimate how many (or what percentage of the positives) are V600E? How many (or what percentage of the positives) are V600K? How many (or what percentage of the positives) are V600 all other mutations?

Download response Molecular pathology BRAF testing 250216